Get the Stockscreener App
9.92
0.30%
0.03
Indaptus Therapeutics Inc stock is traded at $9.92, with a volume of 11,935.
It is up +0.30% in the last 24 hours and up +2,596% over the past month.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
See More
Previous Close:
$9.89
Open:
$9.72
24h Volume:
11,935
Relative Volume:
0.00
Market Cap:
$5.68M
Revenue:
-
Net Income/Loss:
$-15.42M
P/E Ratio:
-5.3913
EPS:
-1.84
Net Cash Flow:
$-13.41M
1W Performance:
-14.48%
1M Performance:
+2,596%
6M Performance:
+944.21%
1Y Performance:
+388.67%
1-Day Range:
$9.62
$10.45
1-Week Range:
$9.62
$12.03
52-Week Range:
$0.2701
$13.40
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Name
Indaptus Therapeutics Inc
Sector
Industry
Phone
(646) 427-2727
Address
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
9.92 | 5.66M | 0 | -15.42M | -13.41M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Indaptus Therapeutics Inc Stock (INDP) Latest News
What analysts say about Indaptus Therapeutics Inc. stockDynamic capital growth - PrintWeekIndia
Is Indaptus Therapeutics Inc. a good long term investmentConsistent triple returns - Autocar Professional
What makes Indaptus Therapeutics Inc. stock price move sharplyFree Access to Community with 300% Return - Newser
Should I buy Indaptus Therapeutics Inc. stock before earningsAccelerated wealth building - jammulinksnews.com
Will Indaptus Therapeutics Inc. stock split in the near futureExceptional market performance - jammulinksnews.com
Indaptus Therapeutics Inc. Stock Analysis and ForecastFree Stock Chart Pattern Guide - jammulinksnews.com
What drives Indaptus Therapeutics Inc. stock priceAccelerated profit realization - jammulinksnews.com
Is Indaptus Therapeutics Inc. stock a good hedge against inflationFree Access to Community - Newser
How high can Indaptus Therapeutics Inc. stock price go in 2025Free Access to Community with 300% Return - Newser
Indaptus Regains Nasdaq Compliance with Bid Price - The Globe and Mail
what makes indaptus therapeutics inc. stock price move sharplyFree Step-by-Step Investment Guide - Newser
Indaptus Therapeutics regains compliance with Nasdaq minimum bid price rule - Investing.com Nigeria
Indaptus Therapeutics (NASDAQ:INDP) Shares Down 3.1% – Should You Sell? - Defense World
How Indaptus Therapeutics Inc. stock performs during market volatilityFree Capital Allocation Plans - Newser
Why Indaptus Therapeutics Inc. stock attracts strong analyst attentionConsistent Growth Alert - Newser
Indaptus Therapeutics Raises $5.7M for R&D Initiatives - The Globe and Mail
Indaptus Therapeutics Inc Stock (INDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):